# Bioequivalence Study of Nisoldipine Extended-Release Tablets, 30 mg

> **NCT00985660** · PHASE1 · COMPLETED · sponsor: **Mylan Pharmaceuticals Inc** · enrollment: 78 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Nisoldipine Extended-release Tablets, 30 mg
- **DRUG:** Sular® Extended Release Tablets, 30 mg

## Key facts

- **NCT ID:** NCT00985660
- **Lead sponsor:** Mylan Pharmaceuticals Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-06
- **Primary completion:** 2007-07
- **Final completion:** 2007-07
- **Target enrollment:** 78 (ACTUAL)
- **Last updated:** 2009-09-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00985660

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00985660, "Bioequivalence Study of Nisoldipine Extended-Release Tablets, 30 mg". Retrieved via AI Analytics 2026-08-24 from https://api.ai-analytics.org/clinical/NCT00985660. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*